Mode
Text Size
Log in / Sign up
Phase 4 N=40 Randomized Triple-blind Treatment

Zonisamide vs. Placebo in the Treatment of Alcohol Dependence

Alcoholism · Alcohol Abuse · Alcohol Dependence

Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Oct 2010
Primary outcome: Primary: Change in Number of Heavy Drinking Days (i.e., 5 or More Drinks Per Day for Men, and 4 or More Per Day for Women)Per Week, by Week — -.30; -.20 Days/week — p=.012

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
zonisamide (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
UConn Health
Primary completion
May 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Number of Heavy Drinking Days (i.e., 5 or More Drinks Per Day for Men, and 4 or More Per Day for Women)Per Week, by Week
-.30; -.20 .012 sig
PRIMARY
Weekly Rate of Change in Abstinent Days
0.17; 0.13 .94
SECONDARY
Change in Number of Drinks Per Week by Week
-2.2; -1.4 .004 sig
SECONDARY
Change in the Urge to Drink Alcohol as Measured by the Alcohol Urge Questionnaire (AUQ)
-1.4; -0.6 .006 sig
SECONDARY
Change in Gamma-glutamyl Transferase (GGT) Concentration
8.4; 2.9 .3

Summary

This is a pilot study designed to examine the potential efficacy and tolerability of zonisamide compared to placebo for the treatment of alcohol dependence.

Eligibility Criteria

Inclusion Criteria

  • age 18 to 65 years, inclusive
  • current Diagnostic & Statistical Manual of Mental Disorders 4th ed (DSM-IV) alcohol dependence (within the past month)
  • have 2 heavy drinking days per week during the period between screening and baseline (defined as >4 standard drinks per day for males, and >3 standard drinks per day for females)
  • able to read at the eighth grade or higher level and show no evidence of significant cognitive impairment
  • if a woman of child-bearing potential (i.e., who has not had a hysterectomy, bilateral oophorectomy, tubal ligation or who is less than two years postmenopausal), must be non-lactating, practicing a reliable method of birth control including barrier method; and have a negative serum pregnancy test prior to initiation of treatment
  • be willing to provide signed, informed consent to participate in the study

Exclusion Criteria

  • have a current, clinically significant physical disease or abnormality (i.e., neurologic, renal, rheumatologic, gastrointestinal, hematologic, pulmonary, endocrine, cardiovascular, hepatic, or autoimmune disease that, in the context of the study would represent a risk to the subject, or significant laboratory abnormalities such as hepatic aminotransferase levels greater than 300% of the uper limit of normal or direct bilirubin levels 150% of the upper limit of normal) on the basis of medical history, physician examination, or routine laboratory evaluation. Serum creatinine level of > 1.2 mg/dl will also be exclusionary. Other specific exclusionary disorders include:
  • patients with a history of renal calculi
  • patients with a history of hypersensitivity to zonisamide or any sulfonamide, Stevens-Johnson Syndrome, penicillin allergy, or history of any severe drug allergic reaction
  • patients with a significant history of systemic autoimmune disease such as lupus erythematosis, fibromyalgia, or rheumatoid arthritis
  • patients with a current blood dyscrasia or a history of such, with the exception of a remote history of iron deficient anemia
  • have a serious psychiatric illness (i.e., schizophrenia, bipolar disorder, severe or psychotic major depression, panic disorder, or substantial suicide or violence risk) on the basis of history or psychiatric examination
  • current dependence on opioids or benzodiazepines or other sedatives will also be exclusionary
  • are considered by investigators to be clinically inappropriate for study participation
  • because individuals with a history of seizure disorder could potentially be at increased risk of experiencing a seizure due to their drinking, such individuals will also be excluded
  • have participated in another pharmacotherapy study in the past thirty days
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00595556). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search